SCHEMBL2676255

SCHEMBL2676255

C=CCNCc1c(C(=O)O)c2ccccc2c(=O)n1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 2/20 0.39
MAPT P10636 3/20 0.39
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
RECQL P46063 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
TOP2A P11388 1/20 0.35
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2675896 0.84 MAPK1 (0.45) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL1718479 0.81 TACR3 (0.43) KDM4EALDH1A1MAPK1NPSR1KMT2A
SCHEMBL2677820 0.81 MAPK1 (0.47) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2676286 0.81 MAPK1 (0.42) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2676253 0.81 MAPK1 (0.42) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2676464 0.81 KDM4E (0.44) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2677075 0.81 MAPK1 (0.42) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2676271 0.79 ESRRA (0.46) ALDH1A1MAPK1NPSR1L3MBTL1POLB
SCHEMBL2676655 0.78 MAPK1 (0.42) KDM4EALDH1A1MAPK1NPSR1L3MBTL1
SCHEMBL2675464 0.78 KDM4E (0.39) KDM4EALDH1A1MAPK1NPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 KDM4E 3176/4885ALDH1A1 2304/4885MAPK1 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.